Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Shield Thera Share News (STX)
STX Share
Price
STX Share
News
STX Share
Chat
STX Share
Trades54
STX
Live RNS
STX Share
Charts
STX Level 2
Console
STX Live
Share Price
STX Broker
Ratings
STX Directors
Deals
STX Financial
Diary
STX
Fundamentals
STX Short
Positions
STX
Media
STX Company
Research
STX Company
Timeline
Share Price Information for Shield Thera (STX)
Last checked at -
Last checked at 
Intraday Shield Thera Share Chart
IN BRIEF: Shield Therapeutics Chief Financial Officer Rudolf to leave
Shield Therapeutics PLC - commercial-stage pharmaceutical company focusing on its iron deficiency product Accrufer - Chief Financial Officer Hans-Peter Rudolf will leave the company next week Friday to pursue other opportunities. The firm's company controller, Paul Spoors, will take on the CFO role on an interim basis. Shield says it has engaged an executive search firm to identify a new CFO.
Current stock price: 6.25 pence, down 6.7% on Thursday
12-month change: down 29%
By Tom Budszus, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Latest STX News
- EARNINGS AND TRADING: ProService Building Services lowers outlook
1 May 2026 - LONDON MARKET MIDDAY: FTSE falls as US-Iran talks stall
1 May 2026 - Shield Therapeutics reports positive Q1 earnings
1 May 2026 - WINNERS & LOSERS: Shield Therapeutics down on Medicaid concerns
1 May 2026 - TRADING UPDATES: Zenith Energy picks up two solar projects in Italy
27 Apr 2026 - Shield Therapeutics expects "strong" Accrufer growth as revenue rises
9 Apr 2026 - Shield's Accrufer MA application accepted in China
3 Mar 2026 - IN BRIEF: Shield Therapeutics gets three more years of US exclusivity
9 Feb 2026
Related News
EARNINGS AND TRADING: ProService Building Services lowers outlook
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported...
LONDON MARKET MIDDAY: FTSE falls as US-Iran talks stall
(Alliance News) - Stock prices in London were lower at midday on Friday, as hopes of diplomatic progress in the Middle East, and a batch of domestic d...
Shield Therapeutics reports positive Q1 earnings
(Sharecast News) - Shield Therapeutics reported first-quarter net revenue of $18m and positive EBIT on Friday, helped by a China milestone payment and...
Shield Thera News
EARNINGS AND TRADING: ProService Building Services lowers outlook
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported...
LONDON MARKET MIDDAY: FTSE falls as US-Iran talks stall
(Alliance News) - Stock prices in London were lower at midday on Friday, as hopes of diplomatic progress in the Middle East, and a batch of domestic d...
Shield Therapeutics reports positive Q1 earnings
(Sharecast News) - Shield Therapeutics reported first-quarter net revenue of $18m and positive EBIT on Friday, helped by a China milestone payment and...
WINNERS & LOSERS: Shield Therapeutics down on Medicaid concerns
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Friday.
TRADING UPDATES: Zenith Energy picks up two solar projects in Italy
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
Shield Therapeutics expects "strong" Accrufer growth as revenue rises
(Alliance News) - Shield Therapeutics PLC on Thursday highlighted a record performance from Accrufer, which it said helped drive a strong rise in annu...
Shield's Accrufer MA application accepted in China
(Sharecast News) - Shield Therapeutics said the Chinese National Medical Products Administration has accepted a marketing authorisation application fo...
IN BRIEF: Shield Therapeutics gets three more years of US exclusivity
Shield Therapeutics PLC - Newcastle, England-based commercial-stage pharmaceutical company - Says the US Food & Drug Administration grants an addition...
Follow the stocks
